Amgen $AMGN
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS67
PHASE 3 / 2-350
RECRUITING30
READOUTS ≤12 MONTHS18
READOUT SLIPPED >6 MO54%
Delay Index: of 52 active trials registered more than a year ago, 28 have moved their primary completion (readout) date by more than 6 months since first registration (median +10.3 months). See all sponsors →
Open Amgen on the live radar map → 📅 $AMGN readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Inebilizumab NCT04540497 |
P3 | Active, not recruiting | IgG4 Related Disease | 135 | 2024-04-09 (+10 mo) |
| MINT NCT04524273 |
P3 | Active, not recruiting | Myasthenia Gravis | 238 | 2024-05-28 (+11 mo) |
| DeLLphi-304 NCT05740566 |
P3 | Active, not recruiting | Small Cell Lung Cancer (SCLC) | 509 | 2025-01-29 (-5 mo) |
| DeLLphi-307 NCT06502977 |
P2 | Active, not recruiting | Extensive Stage Small Cell Lung Cancer | 32 | 2025-03-28 (-6 mo) |
| Maridebart Cafraglutide NCT06660173 |
P2 | Active, not recruiting | Type 2 Diabetes Mellitus (T2DM) | 409 | 2025-10-06 |
| OASIS(EM) NCT03836040 |
P3 | Active, not recruiting | Migraine | 457 | 2025-11-19 (+36 mo) |
| Teprotumumab NCT06248619 |
P3 | Active, not recruiting | Thyroid Eye Disease | 89 | 2025-12-23 (+3 mo) |
| Blinatumomab NCT06054113 |
P2 | Active, not recruiting | B Precursor Acute Lymphoblastic Leukemia; Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia | 18 | 2026-01-06 (+2 mo) |
| Romiplostim NCT03937154 |
P3 | Active, not recruiting | Chemotherapy-induced Thrombocytopenia | 145 | 2026-03-10 (+54 mo) |
| Dazodalibep NCT06245408 |
P3 | Active, not recruiting | Sjögren's Syndrome (SS) | 434 | 2026-10-22 (+8 mo) |
| anvumetostat NCT06593522 |
P2 | Active, not recruiting | MTAP-deleted NSCLC | 61 | 2026-10-31 (-10 mo) |
| MTAPESTRY 101 NCT05094336 |
P1/2 | Active, not recruiting | Advanced MTAP-null Solid Tumors | 329 | 2026-11-30 (+25 mo) |
| Eucalyptus NCT06430866 |
P3 | Active, not recruiting | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | 163 | 2026-12-14 (+12 mo) |
| AMG 732 NCT06401044 |
P1/2 | Active, not recruiting | Thyroid Eye Disease | 94 | 2027-01-06 (-5 mo) |
| MARITIME-1 NCT06858839 |
P3 | Active, not recruiting | Obesity | 3853 | 2027-01-21 |
| MARITIME-2 NCT06858878 |
P3 | Active, not recruiting | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | 1105 | 2027-01-21 |
| Inebilizumab NCT05549258 |
P2 | Recruiting | Neuromyelitis Optica Spectrum Disorder | 15 | 2027-04-13 (+31 mo) |
| Ocrelizumab (US) NCT06700343 |
P3 | Active, not recruiting | Relapsing-remitting Multiple Sclerosis (RRMS) | 152 | 2027-04-19 (+3 mo) |
| MARITIME-3-J NCT06987695 |
P3 | Active, not recruiting | Obesity Disease | 279 | 2027-04-27 (-3 mo) |
| Romosozumab NCT05972551 |
P3 | Active, not recruiting | Osteogenesis Imperfecta | 111 | 2027-05-04 (+2 mo) |
| MARITIME-PEN NCT07871409 |
P3 | Recruiting | Obesity; Overweight | 230 | 2027-06-16 |
| Etelcalcetide NCT03969329 |
P3 | Recruiting | Secondary Hyperparathyroidism | 24 | 2027-06-30 (+60 mo) |
| Sotorasib NCT05920356 |
P3 | Recruiting | Non-Small Cell Lung Cancer (NSCLC) | 750 | 2027-06-30 (+19 mo) |
| Avacopan NCT06321601 |
P3 | Active, not recruiting | Vasculitis | 19 | 2027-07-18 (-33 mo) |
| ABP 938 8 mg NCT07614776 |
P3 | Recruiting | Neovascular Age-related Macular Degeneration; nAMD | 304 | 2027-07-31 |
| MARITIME-OSA-1 NCT07225686 |
P3 | Active, not recruiting | Obesity; Obstructive Sleep Apnea | 250 | 2027-08-20 (-1 mo) |
| Maridebart cafraglutide NCT07441252 |
P2 | Active, not recruiting | Overweight or Obesity and Elevated Liver Fat | 180 | 2027-08-25 |
| MARITIME-OSA-2 NCT07226765 |
P3 | Active, not recruiting | Obstructive Sleep Apnea | 250 | 2027-08-30 |
| DeLLphi-315 NCT07778316 |
P3 | Recruiting | Small Cell Lung Cancer | 400 | 2027-09-24 |
| Blinatumomab NCT04521231 |
P1/2 | Active, not recruiting | B Cell Precursor Acute Lymphoblastic Leukemia | 181 | 2027-11-24 (+57 mo) |
| Maridebart Cafraglutide NCT07684144 |
P3 | Recruiting | Obesity; Overweight | 950 | 2027-12-26 |
| Maridebart cafraglutide NCT07684235 |
P3 | Recruiting | Obesity; Overweight | 3200 | 2027-12-26 |
| DeLLphi-301 NCT05060016 |
P2 | Active, not recruiting | Relapsed/Refractory Small Cell Lung Cancer | 222 | 2027-12-30 (+51 mo) |
| Maridebart Cafraglutide NCT07575399 |
P3 | Recruiting | Obesity or Overweight | 300 | 2028-01-03 |
| ABP 234 NCT06311721 |
P3 | Active, not recruiting | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | 315 | 2028-01-10 (+3 mo) |
| ABP 206 NCT06054555 |
P3 | Active, not recruiting | Melanoma | 633 | 2028-01-25 (+12 mo) |
| HAZEL 401 NCT07438405 |
P2 | Recruiting | Thyroid Eye Disease | 30 | 2028-01-29 |
| PEAPOD NCT04804553 |
P3 | Recruiting | Active Juvenile Psoriatic Arthritis | 60 | 2028-03-21 (+40 mo) |
| Olpasiran NCT05581303 |
P3 | Active, not recruiting | Atherosclerotic Cardiovascular Disease | 7297 | 2028-03-31 (+15 mo) |
| Vitamin D NCT07366086 |
P3 | Recruiting | Osteogenesis Imperfecta | 71 | 2028-04-19 |
| OCEAN(a)-CCTA NCT07293260 |
P3 | Recruiting | Cardiovascular Disease | 406 | 2028-06-15 |
| Pegloticase NCT07388498 |
P3 | Recruiting | Uncontrolled Gout | 270 | 2028-06-18 |
| MARITIME-CV NCT07037433 |
P3 | Active, not recruiting | Atherosclerotic Cardiovascular Disease; Overweight | 12800 | 2028-06-30 |
| MARITIME-HF NCT07037459 |
P3 | Recruiting | Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction | 5056 | 2028-06-30 |
| Sotorasib NCT07172919 |
P2 | Recruiting | Advanced Solid Tumors | 14 | 2028-07-01 (+8 mo) |
| Inebilizumab NCT06570798 |
P2 | Recruiting | Systemic Lupus Erythematosus; Active Refractory Rheumatoid Arthritis | 220 | 2028-08-06 (+20 mo) |
| MARITIME-T2D-3 NCT07866066 |
P3 | Recruiting | Diabetes Mellitus, Type 2 | 1300 | 2028-09-06 |
| CodeBreaK 301 NCT06252649 |
P3 | Recruiting | Metastatic Colorectal Cancer | 450 | 2028-09-25 (+17 mo) |
| Xaluritamig NCT06691984 |
P3 | Active, not recruiting | Metastatic Castration-resistant Prostate Cancer | 707 | 2029-01-02 (+4 mo) |
| DeLLphi-312 NCT07005128 |
P3 | Active, not recruiting | Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer | 350 | 2029-01-04 |
| Etelcalcetide NCT03633708 |
P3 | Recruiting | Secondary Hyperparathyroidism; Chronic Kidney Disease | 56 | 2029-01-31 (+72 mo) |
| DeLLphi-309 NCT06745323 |
P2 | Active, not recruiting | Small Cell Lung Cancer (SCLC) | 252 | 2029-08-10 (+32 mo) |
| Blinatumomab NCT04994717 |
P3 | Active, not recruiting | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | 303 | 2029-09-07 (+50 mo) |
| ROMISTER NCT07700238 |
P3 | Recruiting | Primary Immune Thrombocytopenia | 126 | 2029-09-14 |
| Dazodalibep NCT06747949 |
P3 | Recruiting | Sjögren's Syndrome | 844 | 2029-12-11 (+4 mo) |
| Xaluritamig NCT07213674 |
P3 | Recruiting | Metastatic Castration-resistant Prostate Cancer | 750 | 2030-01-07 (+16 mo) |
| BEAN NCT04528082 |
P3 | Recruiting | Behçet Disease | 60 | 2030-02-07 (+61 mo) |
| THYME NCT06987539 |
P2 | Recruiting | Generalized Myasthenia Gravis | 15 | 2030-03-13 (+2 mo) |
| DeLLphi-305 NCT06211036 |
P3 | Active, not recruiting | Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer | 563 | 2030-04-02 (+31 mo) |
| DeLLphi-306 NCT06117774 |
P3 | Active, not recruiting | Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer | 404 | 2030-04-20 (+42 mo) |
| Blinatumomab NCT07134088 |
P1/2 | Active, not recruiting | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia; Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia | 104 | 2031-03-06 (+27 mo) |
| Inebilizumab NCT07222553 |
P2 | Recruiting | Immunoglobulin G4-related Disease | 15 | 2031-06-10 |
| MERCURY NCT07598825 |
P3 | Recruiting | Autoimmune Hepatitis; AIH | 180 | 2031-07-30 |
| MOMENT NCT07851220 |
P3 | Recruiting | Glomerulonephritis, Membranous | 159 | 2031-09-27 |
| Olpasiran NCT07136012 |
P3 | Recruiting | Cardiovascular Disease | 11000 | 2031-10-20 |
| AUDAX NCT07223190 |
P3 | Not yet recruiting | Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | 560 | 2031-12-30 (+24 mo) |
| Apremilast NCT05767047 |
P3 | Recruiting | Behçet's Disease; Juvenile Psoriatic Arthritis | 48 | 2036-03-17 (+39 mo) |